Designing a novel multi‑epitope vaccine against Ebola virus using reverse vaccinology approach
Abstract Ebola virus (EBOV) is a dangerous zoonotic infectious disease. To date, more than 25 EBOV outbreaks have been documented, the majority of which have occurred in Central Africa. The rVSVG-ZEBOV-GP vaccine (ERVEBO), a live attenuated vaccine, has been approved by the US Food and Drug Administ...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-05-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-022-11851-z |
| _version_ | 1818203716065427456 |
|---|---|
| author | Morteza Alizadeh Hossein Amini-Khoei Shahram Tahmasebian Mahdi Ghatrehsamani Keihan Ghatreh Samani Yadolah Edalatpanah Susan Rostampur Majid Salehi Maryam Ghasemi-Dehnoo Fatemeh Azadegan-Dehkordi Samira Sanami Nader Bagheri |
| author_facet | Morteza Alizadeh Hossein Amini-Khoei Shahram Tahmasebian Mahdi Ghatrehsamani Keihan Ghatreh Samani Yadolah Edalatpanah Susan Rostampur Majid Salehi Maryam Ghasemi-Dehnoo Fatemeh Azadegan-Dehkordi Samira Sanami Nader Bagheri |
| author_sort | Morteza Alizadeh |
| collection | DOAJ |
| description | Abstract Ebola virus (EBOV) is a dangerous zoonotic infectious disease. To date, more than 25 EBOV outbreaks have been documented, the majority of which have occurred in Central Africa. The rVSVG-ZEBOV-GP vaccine (ERVEBO), a live attenuated vaccine, has been approved by the US Food and Drug Administration (FDA) to combat EBOV. Because of the several drawbacks of live attenuated vaccines, multi-epitope vaccines probably appear to be safer than live attenuated vaccines. In this work, we employed immunoinformatics tools to design a multi-epitope vaccine against EBOV. We collected sequences of VP35, VP24, VP30, VP40, GP, and NP proteins from the NCBI database. T-cell and linear B-cell epitopes from target proteins were identified and tested for antigenicity, toxicity, allergenicity, and conservancy. The selected epitopes were then linked together in the vaccine's primary structure using appropriate linkers, and the 50S ribosomal L7/L12 (Locus RL7 MYCTU) sequence was added as an adjuvant to the vaccine construct's N-terminal. The physicochemical, antigenicity, and allergenicity parameters of the vaccine were all found to be satisfactory. The 3D model of the vaccine was predicted, refined, and validated. The vaccine construct had a stable and strong interaction with toll-like receptor 4 (TLR4) based on molecular docking and molecular dynamic simulation (MD) analysis. The results of codon optimization and in silico cloning revealed that the proposed vaccine was highly expressed in Escherichia coli (E. coli). The findings of this study are promising; however, experimental validations should be carried out to confirm these findings. |
| first_indexed | 2024-12-12T03:29:45Z |
| format | Article |
| id | doaj.art-35fd7440f2b643779a984506e90a28f0 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-12-12T03:29:45Z |
| publishDate | 2022-05-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-35fd7440f2b643779a984506e90a28f02022-12-22T00:39:56ZengNature PortfolioScientific Reports2045-23222022-05-0112111510.1038/s41598-022-11851-zDesigning a novel multi‑epitope vaccine against Ebola virus using reverse vaccinology approachMorteza Alizadeh0Hossein Amini-Khoei1Shahram Tahmasebian2Mahdi Ghatrehsamani3Keihan Ghatreh Samani4Yadolah Edalatpanah5Susan Rostampur6Majid Salehi7Maryam Ghasemi-Dehnoo8Fatemeh Azadegan-Dehkordi9Samira Sanami10Nader Bagheri11Department of Tissue Engineering, School of Medicine, Shahroud University of Medical SciencesMedical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical SciencesDepartment of Medical Biotechnology, School of Advanced Technologies, Shahrekord University of Medical SciencesDepartment of Microbiology and Immunology, Faculty of Medicine, Shahrekord University of Medical SciencesClinical Biochemistry Research Center, Basic Health Sciences Institute, Shahrekord University of Medical SciencesCellular and Molecular Research Center, Yasuj University of Medical SciencesDepartment of Molecular Medicine, School of Advanced Medical Science and Technology, Shiraz University of Medical ScienceDepartment of Tissue Engineering, School of Medicine, Shahroud University of Medical SciencesMedical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical SciencesMedical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical SciencesMedical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical SciencesMedical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical SciencesAbstract Ebola virus (EBOV) is a dangerous zoonotic infectious disease. To date, more than 25 EBOV outbreaks have been documented, the majority of which have occurred in Central Africa. The rVSVG-ZEBOV-GP vaccine (ERVEBO), a live attenuated vaccine, has been approved by the US Food and Drug Administration (FDA) to combat EBOV. Because of the several drawbacks of live attenuated vaccines, multi-epitope vaccines probably appear to be safer than live attenuated vaccines. In this work, we employed immunoinformatics tools to design a multi-epitope vaccine against EBOV. We collected sequences of VP35, VP24, VP30, VP40, GP, and NP proteins from the NCBI database. T-cell and linear B-cell epitopes from target proteins were identified and tested for antigenicity, toxicity, allergenicity, and conservancy. The selected epitopes were then linked together in the vaccine's primary structure using appropriate linkers, and the 50S ribosomal L7/L12 (Locus RL7 MYCTU) sequence was added as an adjuvant to the vaccine construct's N-terminal. The physicochemical, antigenicity, and allergenicity parameters of the vaccine were all found to be satisfactory. The 3D model of the vaccine was predicted, refined, and validated. The vaccine construct had a stable and strong interaction with toll-like receptor 4 (TLR4) based on molecular docking and molecular dynamic simulation (MD) analysis. The results of codon optimization and in silico cloning revealed that the proposed vaccine was highly expressed in Escherichia coli (E. coli). The findings of this study are promising; however, experimental validations should be carried out to confirm these findings.https://doi.org/10.1038/s41598-022-11851-z |
| spellingShingle | Morteza Alizadeh Hossein Amini-Khoei Shahram Tahmasebian Mahdi Ghatrehsamani Keihan Ghatreh Samani Yadolah Edalatpanah Susan Rostampur Majid Salehi Maryam Ghasemi-Dehnoo Fatemeh Azadegan-Dehkordi Samira Sanami Nader Bagheri Designing a novel multi‑epitope vaccine against Ebola virus using reverse vaccinology approach Scientific Reports |
| title | Designing a novel multi‑epitope vaccine against Ebola virus using reverse vaccinology approach |
| title_full | Designing a novel multi‑epitope vaccine against Ebola virus using reverse vaccinology approach |
| title_fullStr | Designing a novel multi‑epitope vaccine against Ebola virus using reverse vaccinology approach |
| title_full_unstemmed | Designing a novel multi‑epitope vaccine against Ebola virus using reverse vaccinology approach |
| title_short | Designing a novel multi‑epitope vaccine against Ebola virus using reverse vaccinology approach |
| title_sort | designing a novel multi epitope vaccine against ebola virus using reverse vaccinology approach |
| url | https://doi.org/10.1038/s41598-022-11851-z |
| work_keys_str_mv | AT mortezaalizadeh designinganovelmultiepitopevaccineagainstebolavirususingreversevaccinologyapproach AT hosseinaminikhoei designinganovelmultiepitopevaccineagainstebolavirususingreversevaccinologyapproach AT shahramtahmasebian designinganovelmultiepitopevaccineagainstebolavirususingreversevaccinologyapproach AT mahdighatrehsamani designinganovelmultiepitopevaccineagainstebolavirususingreversevaccinologyapproach AT keihanghatrehsamani designinganovelmultiepitopevaccineagainstebolavirususingreversevaccinologyapproach AT yadolahedalatpanah designinganovelmultiepitopevaccineagainstebolavirususingreversevaccinologyapproach AT susanrostampur designinganovelmultiepitopevaccineagainstebolavirususingreversevaccinologyapproach AT majidsalehi designinganovelmultiepitopevaccineagainstebolavirususingreversevaccinologyapproach AT maryamghasemidehnoo designinganovelmultiepitopevaccineagainstebolavirususingreversevaccinologyapproach AT fatemehazadegandehkordi designinganovelmultiepitopevaccineagainstebolavirususingreversevaccinologyapproach AT samirasanami designinganovelmultiepitopevaccineagainstebolavirususingreversevaccinologyapproach AT naderbagheri designinganovelmultiepitopevaccineagainstebolavirususingreversevaccinologyapproach |